# Glaucoma Detection Model

## Project Overview

This project implements a machine learning model for detecting glaucoma, a serious eye condition that damages the optic nerve and can lead to vision loss or blindness. Early detection is crucial as glaucoma often has no warning signs until later stages, making automated screening tools valuable for preventive care.

## About Glaucoma

Glaucoma is one of the leading causes of blindness, particularly in people over 60. The condition:
- Damages the optic nerve, often due to increased eye pressure
- Develops gradually with no early warning signs
- Can occur at any age but is more common in older adults
- Requires lifelong treatment or monitoring once diagnosed

### Key Risk Factors
- High intraocular pressure
- Age over 55
- Family history of glaucoma
- Certain medical conditions (diabetes, high blood pressure, sickle cell anemia)
- Black, Asian, or Hispanic heritage
- Thin corneas
- Extreme nearsightedness or farsightedness

## Model Performance

The model demonstrates strong performance in glaucoma detection with the following metrics:

### Classification Report

| Class | Precision | Recall | F1-Score | Support |
|-------|-----------|--------|----------|---------|
| **Glaucoma (0)** | 0.93 | 0.96 | 0.94 | 114 |
| **Healthy (1)** | 0.85 | 0.78 | 0.81 | 36 |
| **Accuracy** | - | - | **0.91** | 150 |
| **Macro Avg** | 0.89 | 0.87 | 0.88 | 150 |
| **Weighted Avg** | 0.91 | 0.91 | 0.91 | 150 |

### Metric Interpretation

**Overall Accuracy: 91%**
- The model correctly classifies 91% of all cases (both glaucoma and healthy)

**Class 0 (Glaucoma):**
- **Precision: 93%** - When the model predicts glaucoma, it's correct 93% of the time
- **Recall: 96%** - The model successfully identifies 96% of all glaucoma cases
- **F1-Score: 94%** - Excellent balanced performance for glaucoma detection

**Class 1 (Healthy Eyes):**
- **Precision: 85%** - When the model predicts an eye is healthy, it's correct 85% of the time
- **Recall: 78%** - The model successfully identifies 78% of all healthy eyes
- **F1-Score: 81%** - Good performance, though lower than glaucoma class

## Model Trade-offs

### Class Imbalance
The dataset shows significant class imbalance:
- **Glaucoma cases:** 114 samples (76%)
- **Healthy cases:** 36 samples (24%)

This 3:1 ratio favors glaucoma detection, with better metrics for the majority class.

### Clinical Implications

**False Negatives (Missing Glaucoma - 4% miss rate):**
- Only 4% of glaucoma cases are misclassified as healthy
- **Excellent performance** for the most critical clinical scenario
- Minimizes risk of delayed treatment
- **Impact:** Very low risk of vision loss progression going undetected

**False Positives (Healthy flagged as Glaucoma - 22% error rate):**
- 22% of healthy patients incorrectly flagged as having glaucoma
- Leads to unnecessary follow-up examinations
- May cause patient anxiety and stress
- **Impact:** Increased healthcare costs and patient burden

### Trade-off Analysis

The current model prioritizes **sensitivity over specificity**, which is clinically appropriate for glaucoma screening:

**Strengths:**
- **Outstanding recall (96%) for glaucoma detection** - catches nearly all cases
- High precision (93%) minimizes but doesn't eliminate false alarms
- Strong overall accuracy (91%)
- Clinically appropriate bias toward detecting disease

**Weaknesses:**
- Lower recall (78%) for healthy eyes means more false positives
- 22% of healthy patients will need unnecessary follow-up testing
- May lead to increased healthcare utilization and patient anxiety
- The class imbalance (76% glaucoma) may not reflect real-world prevalence

### Recommendations for Clinical Use

1. **Excellent Screening Tool:** With 96% sensitivity, this model is highly effective for preliminary screening
2. **Confirmation Protocol:** All positive results should still be confirmed by comprehensive ophthalmologic examination
3. **Patient Communication:** Inform patients that positive results require follow-up, but many will be false alarms
4. **Cost-Benefit:** The high sensitivity justifies the 22% false positive rate given glaucoma's severity
5. **Real-World Deployment Considerations:**
   - Glaucoma prevalence in general population is much lower than 76%
   - Model may perform differently when deployed on general screening populations
   - Consider recalibration based on actual population prevalence

## Future Improvements

To enhance model performance, especially for reducing false positives:

1. **Balanced Dataset:** Collect more healthy samples to better reflect real-world prevalence
2. **Threshold Tuning:** Adjust classification threshold to optimize the precision-recall trade-off
3. **Feature Engineering:** Incorporate additional clinical features (age, family history, eye pressure measurements)
4. **Ensemble Methods:** Combine multiple models to improve specificity while maintaining high sensitivity
5. **External Validation:** Test on datasets with different prevalence rates to assess generalizability
6. **Two-Stage Screening:** Use model for initial screening, then apply stricter criteria for high-risk cases

## Clinical Context

This model demonstrates excellent performance for glaucoma detection with:
- **96% sensitivity** - misses only 4% of glaucoma cases
- **93% positive predictive value** - 93% of flagged cases are true glaucoma

The trade-off is a **22% false positive rate** among healthy individuals. This is acceptable for a screening tool because:
- Glaucoma's consequences (irreversible blindness) are severe
- The disease is asymptomatic until late stages
- Follow-up testing is safe and non-invasive
- Early detection enables vision-preserving treatment

**Remember:** Vision loss from glaucoma can be slowed or prevented with early detection and consistent treatment.

## Citation

Medical information sourced from Mayo Clinic guidelines on glaucoma diagnosis and prevention.


## Contact

adey004azeez@gmail.com